Skip to main content

Quercetin attenuates the reduction of parvalbumin in middle cerebral artery occlusion animal model



Calcium is a critical factor involved in modulation of essential cellular functions. Parvalbumin is a calcium buffering protein that regulates intracellular calcium concentrations. It prevents rises in calcium concentrations and inhibits apoptotic processes during ischemic injury. Quercetin exerts potent antioxidant and anti-apoptotic effects during brain ischemia. We investigated whether quercetin can regulate parvalbumin expression in cerebral ischemia and glutamate toxicity-induced neuronal cell death. Adult male rats were treated with vehicle or quercetin (10 mg/kg) 30 min prior to middle cerebral artery occlusion (MCAO) and cerebral cortical tissues were collected 24 h after MCAO. We used various techniques including Western blot, reverse transcription-PCR, and immunohistochemical staining to elucidate the changes of parvalbumin expression.


Quercetin ameliorated MCAO-induced neurological deficits and behavioral changes. Moreover, quercetin prevented MCAO-induced a decrease in parvalbumin expression.


These findings suggest that quercetin exerts a neuroprotective effect through regulation of parvalbumin expression.


Stroke is the most common cause of disability that has a high mortality rate. It is currently ranked as the third leading cause of death in adults. Cerebral ischemia results from a reduction or blocking of cerebral blood flow, which is mainly caused by thrombosis and embolisms [1]. Moreover, it can cause permanent disability, such as movement disorders and cognitive dysfunction [2]. Cerebral ischemic injury causes pathophysiological changes, including excitotoxicity, depolarization, and inflammation. It consequently leads to neuronal cell damage [3].

Quercetin is a flavonoid that presents in rinds and shoots of plants. In particular, it exists abundantly in various vegetables and fruits, including onions, apple, and apricot [4]. Quercetin offers powerful health benefits because it contains potent antioxidants. It is known that quercetin exerts a protective effect in cardiovascular disease and neurodegenerative diseases [5,6,7,8,9]. Moreover, quercetin performs a neuroprotective function by scavenging reactive oxygen species (ROS) and modulating apoptotic pathways in stroke [10, 11]. Quercetin also protects neurons from oxidative stress and intracellular calcium overload [12].

Maintenance of calcium homeostasis is a critical process for the determining cell fate. A rise in intracellular calcium concentration leads to the impairment of crosstalk signaling between calcium ions and ROS, ultimately causes oxidative damage [13]. Moreover, perturbation of intracellular calcium homeostasis can destroy adherens junctions and tight junctions in blood-brain barrier, which can eventually lead to pathological processes in the brain [14]. Interruption of blood circulation in the brain inhibits the supply of oxygen and glucose to neurons, induces excessive calcium influx, and consecutively leads to neuronal excitation [3]. Parvalbumin is a calcium-buffering protein that plays a vital role in reducing calcium overload in neuronal cells [15, 16]. Parvalbumin contains a paired EF-hand domain that has a high-affinity for calcium binding and it regulates intracellular calcium concentration in neurons [17]. It also plays an important role in presynaptic calcium dynamic signaling and synaptic integration [18]. It is strongly expressed in various brain regions, including cortex, hippocampus, thalamus, midbrain, and cerebellum [19]. In this study, we hypothesized that quercetin modulates parvalbumin expression in ischemic brain injury. Previous studies have been reported the neuroprotective effects of quercetin in stroke, but few studies have been shown that quercetin modulates calcium buffer proteins. Thus, we studied the changes of parvalbumin expression by quercetin treatment in a focal ischemic stroke model.


We clearly confirmed the neuroprotective effect of quercetin in MCAO-induced cerebral ischemia using neurobehavioral score evaluation and corner test. MCAO operation induced serious neurological movement deficit in only vehicle-treated animals, whereas quercetin treatment alleviated MCAO-induced movement deficit. Neurological function scores were 3.21 ± 0.44 in vehicle + MCAO animals and 1.53 ± 0.26 in quercetin + MCAO animals, respectively (Fig. 1a). Moreover, the result of corner test showed that quercetin alleviates MCAO injury-induced neurological deficit. The numbers of right turn were 9.44 ± 0.36 and 7.06 ± 0.29 in vehicle + MCAO animals and quercetin + MCAO animals, respectively (Fig. 1b). We screened a decline in parvalbumin expression in the cerebral cortices of vehicle + MCAO animals compared to that of vehicle + sham animals using a proteomic technique. However, this decline was prevented in the presence of quercetin (Fig. 1c). The peptide mass of parvalbumin was 5/103 and the sequence coverage was 40 %. The densitometry levels of the parvalbumin protein spot were 0.34 ± 0.02 and 0.82 ± 0.04 in vehicle + MCAO and quercetin + MCAO animals, respectively (Fig. 1d). RT-PCR and Western blot analyses also clearly showed the changes of parvalbumin expression in the presence of quercetin during ischemic injury (Fig. 2). Parvalbumin transcript levels were decreased in vehicle + MCAO animals compared to that of sham-operated animals. This decrease was prevented in quercetin + MCAO animals (Fig. 2a). Parvalbumin transcripts levels were 0.28 ± 0.03 and 0.73 ± 0.04 in vehicle + MCAO and quercetin + MCAO animals, respectively (Fig. 2b). Quercetin alleviated MCAO-induced decrease in parvalbumin expression (Fig. 2c). Relative parvalbumin protein levels were 0.46 ± 0.02 and 0.93 ± 0.02 in vehicle + MCAO and quercetin + MCAO animals, respectively (Fig. 2d). However, parvalbumin transcript and protein levels were similar between vehicle + sham and quercetin + sham animals. Figure 3 showed that parvalbumin-immunoreactive cells were observed in sham-operated animals regardless of quercetin treatment. However, the number of parvalbumin-positive cells was dramatically decreased in vehicle + MCAO animals, while quercetin treatment attenuated this down-regulation of parvalbumin expression (Fig. 3a). Parvalbumin-positive cells levels were calculated the percentage of the number of positive cells to the number of total cells. Parvalbumin-positive cells levels were 5.88 ± 1.23 and 23.5 ± 2.31 in vehicle + MCAO and quercetin + MCAO animals, respectively (Fig. 3b).

Fig. 1
figure 1

Neurobehavioral scores (a), corner test (b), and proteomic analysis (c and d) of parvalbumin in vehicle + middle cerebral artery occlusion (MCAO), quercetin + MCAO, vehicle + sham, and quercetin + sham animals. Quercetin improves the neurological deficit score and tendency of turning towards to the right by ischemic stroke. Data (n = 16) are represented as the mean ± S.E.M. * p < 0.01, ** p < 0.05 vs. the vehicle + sham group, # p < 0.05 vs. vehicle + MCAO group. Squares indicate parvalbumin protein spots (c). Spot intensities were measured by PDQuest software. Spot intensities are reported as a ratio relative to vehicle + sham animals (d). Data (n = 4) are shown as means ± S.E.M. * p < 0.05. Mw and pI indicate molecular weight and isoelectric point, respectively

Fig. 2
figure 2

Reverse transcription-PCR (a and b) and Western blot (c and d) of parvalbumin in vehicle + middle cerebral artery occlusion (MCAO), quercetin + MCAO, vehicle + sham, and quercetin + sham groups. Densitometric analyses from reverse transcription-PCR and Western blot are represented as a ratio of parvalbumin intensity to β-actin intensity. Each lane represents an individual animal. Data (n = 4) are shown as means ± S.E.M. * p < 0.05

Fig. 3
figure 3

Immuno-staining of parvalbumin in vehicle + middle cerebral artery occlusion (MCAO), quercetin + MCAO, vehicle + sham, and quercetin + sham groups. Arrows indicate positive cells of parvalbumin (a). Scale bar = 100 µm. Parvalbumin-positive cells levels were expressed as percentage of the number of parvalbumin positive cells to that of total cells (b). Data (n = 4) are shown as means ± S.E.M. * p < 0.05


Brain ischemic injury causes oxidative stress and consequently leads to neuronal cell death and neurodegenerative disorders [20, 21]. We previously demonstrated that quercetin exerts a potent neuroprotective effect against MCAO-induced brain injury and glutamate-induced cell death [22]. Quercetin improves MCAO-induced neurological deficit scores and attenuates neuronal damage after MCAO [22, 23]. Quercetin dramatically reduces infarction and protects neuronal cells against cerebral ischemia through modulation of various proteins [22, 23]. Previous reports have showed that quercetin exerts neuroprotective effects in both in vivo and in vitro experimental models [24, 25]. Also, quercetin protects the blood brain barrier and reduces neuronal damage in brain ischemia by scavenging ROS [26]. We recently reported that quercetin alleviated the decrease of neuronal marker NeuN in the ischemic damaged cerebral cortex [27]. Neuronal markers indicate activation of neurons. Thus, the regulation of NeuN by quercetin represents mitigation of nerve damage in ischemic brain injury. Our previous and current studies explained that quercetin prevented the decrease of neuronal marker expression as well as parvalbumin expression in ischemic brain injury. Our results can demonstrated that quercetin exerts neuroprotective effect by regulating various proteins such as parvalbumin and neuronal marker. This study focused on the regulation of expression of parvalbumin in cerebral ischemic animal models.

Ischemic brain injury causes an increase in intracellular calcium, activates apoptotic signaling pathways, and subsequently leads to nervous system disorders [28,29,30]. Increased oxidative stress causes intracellular calcium overload, impairs mitochondrial function, and leads to apoptosis [31, 32]. Parvalbumin rescues neurons by attenuating cytotoxic calcium overload in neuronal cell injury [33]. Moreover, over-expression of parvalbumin protects neurons against ischemic injury-induced cell death [34]. Transient forebrain ischemia reduces parvalbumin immunoreactivity in the hippocampus and decline in parvalbumin expression leads to structural damage in neurons [35, 36]. Parvalbumin expression is also reduced in neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease [37, 38]. We identified that quercetin attenuates MCAO-induced a reduction in parvalbumin expression using a proteomic approach. Moreover, Western blot and reverse transcription-PCR analyses showed that quercetin mitigates MCAO-induced a decrease in parvalbumin. In addition, immunohistochemical study elucidated that quercetin treatment alleviates a decrease in the number of parvalbumin-positive cell following MCAO-induced injury. These results demonstrate that quercetin regulates parvalbumin expression in focal cerebral ischemia.

We clearly demonstrated that quercetin can regulate parvalbumin expression. Parvalbumin is a calcium-buffering protein that is abundantly distributed in GABAergic interneurons of the cerebral cortex and hippocampus [39, 40]. Parvalbumin is an essential protein for maintaining calcium homeostasis in neurons by reducing intracellular calcium levels [41]. High levels of intracellular calcium can lead to apoptosis and subsequently cause nervous system disorders [30]. Thus, perturbation of intracellular calcium homeostasis is considered to be a major pathological mechanism in stroke [42, 43].


This study clearly showed that quercetin has a neuroprotective effect on deteriorated neurological function in MCAO injury. Furthermore, we demonstrated that quercetin alleviates down-regulation of parvalbumin expression during ischemic brain injury. Therefore, our findings suggest that quercetin might exert its neuroprotective functions by modulation of parvalbumin expression in MCAO-injured animals.


Experimental animals

Adult male Sprague-Dawley rats (220–230 g, n = 64, Samtako Co, Osan, Korea) were housed at controlled light condition (12 h light/12 h dark cycle, light on at 6:00 AM to 6:00 PM) and temperature (25°C). Feed and water were freely supplied. All experimental processes were taken to minimize the suffering of animals, approved by the Institutional Animal Care and Use Committee of Gyeongsang National University, and carried out provided guideline. Animals were randomly divided into four groups as follows: vehicle + middle cerebral artery occlusion (MCAO), quercetin + MCAO, vehicle + sham, and quercetin + sham. Quercetin (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.1 % dimethyl sulfoxide (DMSO) with phosphate buffered saline (PBS). Quercetin (10 mg/kg) or vehicle was intraperitoneally injected 30 min before MCAO operation [11]. Vehicle animals were administered only a solvent solution without quercetin.

Middle cerebral artery occlusion surgical procedure

MCAO was performed through insertion of intraluminal nylon to induce focal cerebral ischemia [44]. Animal was anesthetized with Zoletil (Virbac, Carros, France) at 50 mg/kg and placed on surgical plate with supine position. A warming pad was used to maintain body temperature during surgical process and midline of neck skin region was incised. Right common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were exposed by separation of surrounding tissues. CCA was temporally blocked with a microvascular clip and ECA was tied. A 4/0 nylon filament with rounded tip by flame heating was inserted into the incision of ECA. Inserted filament was advanced to the lumen of the ICA until a slight resistance was felt. The origin of middle cerebral artery was occluded by the end of nylon filament. After the occlusion, nylon filament was ligated with ECA to remain stationary and skin incision was sutured with silk. Sham animals as control were operated by same procedure except the nylon insertion step. Neurofunction and corner tests were performed 24 hours after MCAO surgery and started at 10:00 AM. Animals were sacrificed after behavior test and brain tissues were collected. Whole brains were fixed in 4 % neutral buffered paraformaldehyde for morphological study and cerebral cortices were isolated from brain tissues and kept at -70°C for protein and RNA works.

Neurological functional test and corner test

Neurological functional test was carried out as described methods [45, 46]. Neurological function was scored by an investigator who was blind to the experimental design. Criteria of neurological functional test was as follows: 0 indicates normal neurological function status; 1 indicates mild neurological deficit status (forelimb of the contralateral side is flexed when the animal is lifted by tail); 2 indicates moderate neurological deficit status (circling to the contralateral side when moving forward); 3 indicates severe neurological deficit status (falling to the contralateral side when moving forward); 4 indicates unconscious state and no movement. In addition, corner test was performed to evaluate sensorimotor dysfunction [47]. Animals were placed between two boards with dimensions of 30 × 20 × 1 cm3. Two boards were facing each other at an angle of 30° with a slight gap to guide the animal towards the edge. Animals were placed facing the corners and moved forward, and both vibrissae were simultaneously stimulated. After stimulation, animals turned to the left or right direction and came out in the opposite direction of the corners. Animals were trained for corner test seven days prior to MCAO surgery. The number of turns to the right (ipsilateral side of the damaged brain) from the corner in ten times trial was measured and incomplete turn was excluded from the measurement.

Two Dimensional Electrophoresis (2DE)

Right cerebral cortexes (100 mg) were homogenized with 200 µl of lysis buffer (8 M urea, 4 % CHAPS, ampholytes, and 40 mM Tris-HCl) and lysed by sonication for 3 min. Lysate was centrifuged at 16,000 g for 20 min at 4°C and supernatant was collected. And then supernatant was mixed with same volume of 20 % trichloroacetic acid and centrifuged 16,000 g for 15 min at 4°C. After centrifugation, supernatant was discarded and protein pellet was washed with 90 % acetone. Dried protein pellet was dissolved with lysis buffer and protein concentration was measured by Bradford protein assay kit (Bio-Rad, Hercules, CA, USA). For first dimensional isoelectric focusing (IEF), protein sample (50 µg) was mixed with rehydration buffer [8 M urea, 2 % CHAPS, 20 mM dithiothreitol (DTT), 0.5 % immobilized pH gradient (IPG) buffer, and bromophenol blue], loaded on IPG gel strip (17 cm, pH 4–7, Bio-Rad), and rehydrated for 13 h. IPG strip containing protein sample was run at 250 V for 15 min, 10,000 V for 3 h, and then 10,000 V to 50,000 V on Ettan IPGphor 3 System (GE Healthcare, Uppsala, Sweden). Strips were immersed with equilibration buffer [6 M urea, 30 % glycerol, 2 % sodium dodecyl sulfate, and 50 mM Tris-HCl (pH 8.8)] containing 1 % DTT for 15 min and subsequently incubated with same solution that containing 2.5 % iodoacetamide instead of DTT. For second dimensional electrophoresis, strip was overlaid onto 12 % acrylamide gel and run at 15 mA for 15 h using Protean-II XI electrophoresis equipment (Bio-Rad). Acrylamide gels were fixed in solution containing 12 % acetic acid and 50 % methanol, and washed in 50 % ethanol. They were sensitized with 0.02 % sodium thiosulfate, stained in 0.2 % silver nitrate solution, and developed with 2 % sodium carbonate. Silver-stained gel image was digitized by Agfa ARCUS 1200™ (Agfa-Gevaert, Mortsel, Belgium) and analyzed by PDQuest 2-D analysis software (Bio-Rad). Targeted protein spots were removed from gel, destained, and freeze-dried. They were alkylated and digested with trypsin-containing buffer. Digested peptide samples were mixed with matrix solution containing 0.02 % α-cyano-4-hydroxycinnamic acid and placed on metal plate. Voyager System DE-STR MALDI-TOF mass spectrometer was used to analyze peptide samples and analyzed peptide was detected by MS-Fit and ProFound programs. Based on peptide mass data, peptide sequences were obtained from SWISS-prot and NCBI databases.

Reverse Transcription‐Polymerase Chain Reaction (RT-PCR)

Total RNA was extracted from right cerebral cortex using Trizol Reagent (Life Technologies, Rockville, MD, USA) and reverse transcribed into complementary DNA using Superscript III firststrand system (Invitrogen, Carlsbad, CA, USA) according to the recommended protocol of manufacturer. Parvalbumin-coded gene was detected from synthetized complementary DNA and amplified by PCR method. Used primer sequences were as follows: parvalbumin, forward primer: 5-AAGAGTGCGGATGATGTGAAG-3’, reverse primer: 5-AGCCATCAGCGTCTTTGTTT-3’; β-actin, forward primer: 5-GGGTCAGAAGGACTCCTACG-3’, reverse primer: 5-GGTCTCAAACATGATCTGGG-3’. PCR was performed for thirty cycles and PCR conditions were as follows: initial denaturation and polymerase activation at 94℃ for 5 min, denaturation at 95°C for 30 sec, primer annealing at 52.5°C for 30 sec, and elongation at 72°C for 30 sec. Amplified target DNA products were mixed with LoadingSTAR dye (Dyne Bio, Seongnam, Korea) and loaded on 1 % agarose gel. Loaded product bands were visualized by ultra-violet light exposure.

Western blot analysis

Immunoblot analysis was carried out as a previously described method [48]. Samples from right cerebral cortexes were homogenized in lysis buffer [1 % Triton X-100 and 1 mM EDTA in PBS (pH 7.4)] using a tissue homogenizer and centrifuged at 16,000 g for 20 min at 4°C. Supernatant was isolated and protein concentration of each sample was calculated with bicinchroninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s manual. Protein (30 µg) from each sample was loaded on 10 % sodium dodecyl sulfate poly-acrylamide gel electrophoresis and electrophoresed until dye went down to the bottom. Protein was transferred to a poly-vinylidene fluoride membrane and membranes were incubated with 5 % skim milk in tris-buffer saline containing 0.1 % Tween-20 (TBST) for 1 h. Membranes were washed three times with TBST for 10 min and reacted with following primary antibodies: anti-parvalbumin (1:1,000; Thermo Fisher Scientific) and anti-β-actin (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. They were washed with TBST and incubated with horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG (1:5,000; Thermo Fisher Scientific) for 2 h. Membranes were washed with TBST and reacted with enhanced chemiluminescence Western detection reagents (GE Healthcare) according to the manufacturer’s manual.


Fixed brain tissues were washed with tap water, dehydrated with graded ethyl alcohol (70–100 %), and cleaned with xylene. Brain tissues were embedded with paraffin and sectioned with 4 µm thickness. Sections were deparaffinized with xylene, rehydrated with graded ethyl alcohol (100–70 %), and immersed in sodium citrate buffer (0.01 M, pH 6.0) using a microwave oven for antigen retrieval. Sections were treated with 1 % hydrogen peroxide in methanol for 10 min to exhaust peroxidase activity. They were incubated with normal goat serum for 1 h to block non-specific reaction and reacted with anti-parvalbumin primary antibody (1:100, Thermo Fisher Scientific) overnight at 4°C. They were washed with PBS and treated with biotin-conjugated secondary antibody for 2 h. After washing with PBS, sections were incubated with avidin-biotin-peroxidase complex (Vector Laboratories Inc, Burlingame, CA, USA) for 2 h. Brain sections were stained with 3, 3’-diaminiobenzidine (DAB, Sigma-Aldrich) for 15 min and hydrogen peroxide was added. Sections were counterstained with hematoxylin, washed with water, dehydrated with graded ethyl alcohol (70–100 %), and cleaned with xylene. Stained tissues were mounted with permount solution (Thermo Fisher Scientific) and observed with Zeiss Axioskop light microscope (Carl Zeiss, Jena, Germany). Five fields from cerebral cortex region were randomly selected and the number of parvalbumin-positive cells was counted. Parvalbumin-positive cells levels were expressed as percentage of the number of parvalbumin positive cells to that of total cells.

Statistical analysis

Data were presented as means ± standard error of mean (S.E.M.). Results of each groups were compared by two-way analysis of variance (ANOVA) followed by post-hoc Scheffe’s test. p < 0.05 was considered to be statistically significant.

Availability of data and materials

The data that support the findings of this study are available on request from the corresponding author on reasonable request.



Two dimensional electrophoresis


Bicinchroninic acid


Common carotid artery




Dimethyl sulfoxide




External carotid artery


Internal carotid artery


Isoelectric focusing


Immobilized pH gradient


Middle cerebral artery occlusion


Phosphate-buffered saline


Reactive oxygen species


Reverse-transcript polymerase chain reaction


Poly-vinylidene fluoride


Tris-buffered saline containing 0.1 % Tween-20


  1. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009;7:97.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  2. Mercier L, Audet T, Hébert R, Rochette A, Dubois MF. Impact of motor, cognitive, and perceptual disorders on ability to perform activities of daily living after stroke. Stroke. 2001;32(11):2602–8.

    CAS  PubMed  Article  Google Scholar 

  3. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391–7.

    CAS  PubMed  Article  Google Scholar 

  4. Sultana B, Anwar F. Flavonols (kaempeferol, quercetin, myricetin) contents of selected fruits, vegetables and medicinal plants. Food Chem. 2008;108(3):879–84.

    CAS  PubMed  Article  Google Scholar 

  5. Clifton PM. Effect of grape seed extract and quercetin on cardiovascular and endothelial parameters in high-risk subjects. J Biomed Biotechnol. 2004;4(5):272–8.

    Article  Google Scholar 

  6. Karuppagounder SS, Madathil SK, Pandey M, Haobam R, Rajamma U, Mohanakumar KP. Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson’s disease in rats. Neuroscience. 2013;236:136–48.

    CAS  PubMed  Article  Google Scholar 

  7. Rivera F, Costa G, Abin A, Urbanavicius J, Arruti C, Casanova G, Dajas F. Reduction of ischemic brain damage and increase of glutathione by a liposomal preparation of quercetin in permanent focal ischemia in rats. Neurotox Res. 2008;13(2):105–14.

    CAS  PubMed  Article  Google Scholar 

  8. Sabogal-Guáqueta AM, Muñoz-Manco JI, Ramírez-Pineda JR, Lamprea-Rodriguez M, Osorio E, Cardona-Gómez GP. The flavonoid quercetin ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice. Neuropharmacology. 2015;93:134–45.

    PubMed  Article  CAS  Google Scholar 

  9. van Erk MJ, Roepman P, van der Lende TR, Stierum RH, Aarts JM, van Bladeren PJ, van Ommen B. Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005;44(3):143–56.

    PubMed  Article  CAS  Google Scholar 

  10. Lu XL, Zhao CH, Yao XL, Zhang H. Quercetin attenuates high fructose feeding-induced atherosclerosis by suppressing inflammation and apoptosis via ROS-regulated PI3K/AKT signaling pathway. Biomed Pharmacother. 2017;85:658–71.

    CAS  PubMed  Article  Google Scholar 

  11. Yao RQ, Qi DS, Yu HL, Liu J, Yang LH, Wu XX. Quercetin attenuates cell apoptosis in focal cerebral ischemia rat brain via activation of BDNF-TrkB-PI3K/Akt signaling pathway. Neurochem Res. 2012;37(12):2777–86.

    CAS  PubMed  Article  Google Scholar 

  12. Sakanashi Y, Oyama K, Matsui H, Oyama TB, Oyama TM, Nishimura Y, Sakai H, Oyama Y. Possible use of quercetin, an antioxidant, for protection of cells suffering from overload of intracellular Ca2+: a model. Life Sci. 2008;83(5–6):164–9.

    CAS  PubMed  Article  Google Scholar 

  13. Feissner RF, Skalska J, Gaum WE, Sheu SS. Crosstalk signaling between mitochondrial Ca2+ and ROS. Front Biosci (Landmark Ed). 2009;14:1197–218.

    CAS  Article  Google Scholar 

  14. Brown RC, Davis TP. Calcium modulation of adherens and tight junction function: a potential mechanism for blood-brain barrier disruption after stroke. Stroke. 2002;33(6):1706–11.

    CAS  PubMed  Article  Google Scholar 

  15. Baimbridge K, Celio M, Rogers J. Calcium binding proteins in the nervous system. Trends Neurosci. 1992;15(8):303–8.

    CAS  PubMed  Article  Google Scholar 

  16. Schwaller B. The continuing disappearance of pure Ca2+ buffers. Cell Mol Life Sci. 2009;66(2):275–300.

    CAS  PubMed  Article  Google Scholar 

  17. Pauls TL, Durussel I, Berchtold MW, Cox JA. Inactivation of individual Ca2+-binding sites in the paired EF-hand sites of parvalbumin reveals asymmetrical metal-binding properties. Biochemistry. 1994;33(34):10393–400.

    CAS  PubMed  Article  Google Scholar 

  18. Collin T, Chat M, Lucas MG, Moreno H, Racay P, Schwaller B, Marty A, Llano I. Developmental changes in parvalbumin regulate presynaptic Ca2+ signaling. J Neurosci. 2005;25(1):96–107.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. Celio MR. Calbindin D-28k and parvalbumin in the rat nervous system. Neuroscience. 1990;35(2):375–475.

    CAS  PubMed  Article  Google Scholar 

  20. Braughler JM, Hall ED. Central nervous system trauma and stroke. I. Biochemical considerations for oxygen radical formation and lipid peroxidation. Free Radic Biol Med. 1989;6(3):289–301.

    CAS  PubMed  Article  Google Scholar 

  21. Hall ED, Braughler JM. Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic Biol Med. 1989;6(3):303–13.

    CAS  PubMed  Article  Google Scholar 

  22. Park DJ, Shah FA, Koh PO. Quercetin attenuates neuronal cells damage in a middle cerebral artery occlusion animal model. J Vet Med Sci. 2018;80(4):676–83.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. Shah FA, Park DJ, Koh PO. Identification of proteins differentially expressed by quercetin treatment in a middle cerebral artery occlusion model: A proteomics approach. Neurochem Res. 2018;43(8):1608–23.

    CAS  PubMed  Article  Google Scholar 

  24. Cho JY, Kim IS, Jang YH, Kim AR, Lee SR. Protective effect of quercetin, a natural flavonoid against neuronal damage after transient global cerebral ischemia. Neurosci Letts. 2006;404(3):330–5.

    CAS  Article  Google Scholar 

  25. Wang XQ, Yao RQ, Liu X, Huang JJ, Qi DS, Yang LH. Quercetin protects oligodendrocyte precursor cells from oxygen/glucose deprivation injury in vitro via the activation of the PI3K/Akt signaling pathway. Brain Res Bull. 2011;86(3–4):277–84.

    CAS  PubMed  Article  Google Scholar 

  26. Lapi D, Vagnani S, Pignataro G, Esposito E, Paterni M, Colantuoni A. Protective effects of Quercetin on rat pial micro-vascular changes during transient bilateral common carotid artery occlusion and reperfusion. Front Physiol. 2012;3:32.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Park DJ, Jeon SJ, Kang JB, Koh PO. Quercetin reduces ischemic brain injury by preventing ischemia-induced decreases in the neuronal calcium sensor protein hippocalcin. Neuroscience. 2020;15:430:47–62.

  28. Orrenius S, Gogvadze V, Zhivotovsky B. Calcium and mitochondria in the regulation of cell death. Biochem Biophys Res Commun. 2015;460(1):72–81.

    CAS  PubMed  Article  Google Scholar 

  29. Silver IA, Erecińska M. Intracellular and extracellular changes of [Ca2+] in hypoxia and ischemia in rat brain in vivo. J Gen Physiol. 1990;95(5):837–66.

    CAS  PubMed  Article  Google Scholar 

  30. Starkov AA, Chinopoulos C, Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium. 2004;36(3–4):257–64.

    CAS  PubMed  Article  Google Scholar 

  31. Joseph JA, Strain JG, Jimenez ND, Fisher D. Oxidant injury in PC12 cells-a possible model of calcium “dysregulation” in aging, I. Selectivity of protection against oxidative stress. J Neurochem. 1997;69(3):1252–8.

    CAS  PubMed  Article  Google Scholar 

  32. Trump BF, Berezesky IK. Calcium-mediated cell injury and cell death. FASEB J. 1995;9(2):219–28.

    CAS  PubMed  Article  Google Scholar 

  33. Koh PO. Estradiol ameliorates the reduction in parvalbumin expression induced by ischemic brain injury. Neurosci Lett. 2014;574:36–40.

    CAS  PubMed  Article  Google Scholar 

  34. Dekkers J, Bayley P, Dick JR, Schwaller B, Berchtold MW, Greensmith L. Over-expression of parvalbumin in transgenic mice rescues motoneurons from injury-induced cell death. Neuroscience. 2004;123(2):459–66.

    CAS  PubMed  Article  Google Scholar 

  35. Araki T, Kato H, Liu XH, Kogure K, Kato K, Itoyama Y. An immunohistochemical study of parvalbumin containing interneurons in the gerbil hippocampus after cerebral ischemia. Metab Brain Dis. 1994;9(3):225–34.

    CAS  PubMed  Article  Google Scholar 

  36. Tortosa A, Ferrer I. Parvalbumin immunoreactivity in the hippocampus of the gerbil after transient forebrain ischaemia: a qualitative and quantitative sequential study. Neuroscience. 1995;55(1):33–43.

    Article  Google Scholar 

  37. Lanoue AC, Blatt GJ, Soghomonian JJ. Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson’s disease. Brain Res. 2013;1531:37–47.

    CAS  PubMed  Article  Google Scholar 

  38. Satoh J, Tabira T, Sano M, Nakayama H, Tateishi J. Parvalbumin-immunoreactive neurons in the human central nervous system are decreased in Alzheimer’s disease. Acta Neuropathol. 1991;81(4):388–95.

    CAS  PubMed  Article  Google Scholar 

  39. Celio MR. Parvalbumin in most gamma-aminobutyric acid-containing neurons of the rat cerebral cortex. Science. 1986;231(4741):995–7.

    CAS  PubMed  Article  Google Scholar 

  40. Klausberger T, Marton LF, O’Neill J, Huck JH, Dalezios Y, Fuentealba P, Suen WY, Papp E, Kaneko T, Watanabe M, Csicsvari J, Somogyi P. Complementary roles of cholecystokinin- and parvalbumin-expressing GABAergic neurons in hippocampal network oscillations. J Neurosci. 2005;25(42):9782–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. Girard F, Meszar Z, Marti C, Davis FP, Celio M. Gene expression analysis in the parvalbumin-immunoreactive PV1 nucleus of the mouse lateral hypothalamus. Eur J Neurosci. 2011;34(12):1934–43.

    CAS  PubMed  Article  Google Scholar 

  42. Choi DW. Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci. 1995;18(2):58–60.

    CAS  PubMed  Article  Google Scholar 

  43. Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity. Cell Calcium. 2010;47(2):122–9.

    CAS  PubMed  Article  Google Scholar 

  44. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91.

    CAS  Article  PubMed  Google Scholar 

  45. Jin Z, Liang J, Wang J, Kolattukudy PE. MCP-induced protein 1 mediates the minocycline-induced neuroprotection against cerebral ischemia/reperfusion injury in vitro and in vivo. J Neuroinflammation. 2015;12:39.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  46. Koh PO. Cerebral ischemic injury decreases α-synuclein expression in brain tissue and glutamate-exposed HT22 cells. Lab Anim Res. 2017;33(3):244–50.

    PubMed  PubMed Central  Article  Google Scholar 

  47. Shamsaei N, Erfani S, Fereidoni M, Shahbazi A. Neuroprotective effects of exercise on brain edema and neurological movement disorders following the cerebral ischemia and reperfusion in rats. Basic Clin Neurosci. 2017;8(1):77–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Jang AR, Koh PO. Ischemic brain injury decreases dynamin-like protein 1 expression in a middle cerebral artery occlusion animal model and glutamate-exposed HT22 cells. Lab Anim Res. 2016;32(4):194–9.

    PubMed  PubMed Central  Article  Google Scholar 

Download references


Not applicable.


This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST)(NRF-2018R1D1A1B07044074).

Author information

Authors and Affiliations



D-JP, J-BK, F-AS performed experiment, organized and analyzed data. P-OK designed the experiment, wrote and corrected the manuscript, and managed general research and drafting. All authors read and approved this final manuscript.

Corresponding author

Correspondence to Phil-Ok Koh.

Ethics declarations

Competing interests

The authors declare that there is no financial conflict of interests to publish these results.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Park, DJ., Kang, JB., Shah, FA. et al. Quercetin attenuates the reduction of parvalbumin in middle cerebral artery occlusion animal model. Lab Anim Res 37, 9 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Cerebral ischemia
  • Neuroprotection
  • Parvalbumin
  • Quercetin